MyMD Pharmaceuticals (MYMD) Competitors $0.10 +0.00 (+0.79%) As of 08/18/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock MYMD vs. PTPI, SRNE, ZVSA, PBLA, BPTSY, HEPA, VIRX, VINC, NCNA, and TRVNShould you be buying MyMD Pharmaceuticals stock or one of its competitors? The main competitors of MyMD Pharmaceuticals include Petros Pharmaceuticals (PTPI), Sorrento Therapeutics (SRNE), ZyVersa Therapeutics (ZVSA), Panbela Therapeutics (PBLA), Biophytis (BPTSY), Hepion Pharmaceuticals (HEPA), Viracta Therapeutics (VIRX), Vincerx Pharma (VINC), NuCana (NCNA), and Trevena (TRVN). These companies are all part of the "pharmaceutical products" industry. MyMD Pharmaceuticals vs. Its Competitors Petros Pharmaceuticals Sorrento Therapeutics ZyVersa Therapeutics Panbela Therapeutics Biophytis Hepion Pharmaceuticals Viracta Therapeutics Vincerx Pharma NuCana Trevena Petros Pharmaceuticals (NASDAQ:PTPI) and MyMD Pharmaceuticals (NASDAQ:MYMD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations. Do institutionals & insiders hold more shares of PTPI or MYMD? 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.6% of MyMD Pharmaceuticals shares are owned by institutional investors. 12.3% of Petros Pharmaceuticals shares are owned by insiders. Comparatively, 2.1% of MyMD Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is PTPI or MYMD more profitable? Petros Pharmaceuticals' return on equity of -78.22% beat MyMD Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Petros PharmaceuticalsN/A -78.22% -23.50% MyMD Pharmaceuticals N/A -179.05%-108.14% Which has higher valuation & earnings, PTPI or MYMD? MyMD Pharmaceuticals has lower revenue, but higher earnings than Petros Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPetros Pharmaceuticals$5.11M0.18-$8.16M-$52.910.00MyMD PharmaceuticalsN/AN/A-$4MN/AN/A Does the media prefer PTPI or MYMD? In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled MyMD Pharmaceuticals'average media sentiment score. Company Overall Sentiment Petros Pharmaceuticals Neutral MyMD Pharmaceuticals Neutral Which has more risk and volatility, PTPI or MYMD? Petros Pharmaceuticals has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals has a beta of 2.15, suggesting that its stock price is 115% more volatile than the S&P 500. SummaryPetros Pharmaceuticals beats MyMD Pharmaceuticals on 5 of the 7 factors compared between the two stocks. Get MyMD Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MYMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MYMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYMD vs. The Competition Export to ExcelMetricMyMD PharmaceuticalsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$241K$17.90M$5.76B$9.65BDividend YieldN/AN/A3.91%4.09%P/E RatioN/AN/A30.7825.12Price / SalesN/A18.76456.64116.46Price / CashN/AN/A25.2228.45Price / Book0.010.019.375.95Net Income-$4M-$15.34M$3.26B$265.46M7 Day Performance-7.37%0.59%1.88%0.96%1 Month PerformanceN/A-0.30%3.73%2.47%1 Year Performance-94.34%-41.64%28.93%20.24% MyMD Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYMDMyMD PharmaceuticalsN/A$0.10+0.8%N/A-94.4%$241KN/A0.006High Trading VolumePTPIPetros PharmaceuticalsN/A$0.03-2.1%N/A-99.7%$885K$5.11M-0.0120Gap DownSRNESorrento Therapeutics0.6682 of 5 stars$0.00-34.8%N/A-75.6%$827K$60.32M0.00800Gap DownZVSAZyVersa Therapeutics0.7111 of 5 stars$0.16-2.5%N/A-94.7%$780KN/A0.002Gap DownPBLAPanbela Therapeutics0.9506 of 5 stars$0.16-7.1%N/A-57.2%$767KN/A0.006Short Interest ↓Gap DownBPTSYBiophytisN/A$1.81flatN/AN/A$634KN/A0.0030News CoverageShort Interest ↓HEPAHepion Pharmaceuticals1.0734 of 5 stars$0.05+16.2%N/A-99.8%$533KN/A-0.0120Short Interest ↓Gap UpVIRXViracta Therapeutics1.7544 of 5 stars$0.01flat$1.75+17,793.7%N/A$389KN/A-0.0120Negative NewsVINCVincerx Pharma2.7232 of 5 stars$0.07+91.7%$40.00+61,438.5%-99.7%$340KN/A0.0060NCNANuCana3.5564 of 5 stars$0.04-4.7%$25.00+61,628.4%-99.4%$246KN/A-0.0130News CoverageUpcoming EarningsAnalyst UpgradeTRVNTrevena1.1489 of 5 stars$0.25-72.5%$5.00+1,900.0%-93.0%$240K$443K-0.0140Short Interest ↑Gap Down Related Companies and Tools Related Companies PTPI Alternatives SRNE Alternatives ZVSA Alternatives PBLA Alternatives BPTSY Alternatives HEPA Alternatives VIRX Alternatives VINC Alternatives NCNA Alternatives TRVN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYMD) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MyMD Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MyMD Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access